Pacira Pharmaceuticals Inc. (PCRX)

35.30
NASDAQ : Health Technology
Prev Close 35.30
Day Low/High 0.00 / 0.00
52 Wk Low/High 26.95 / 52.48
Avg Volume 1.18M
Exchange NASDAQ
Shares Outstanding 40.71M
Market Cap 1.44B
EPS -1.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

University Of Tennessee Medical Center At Knoxville, Pacira Pharmaceuticals, And CQ-Insights Announce Collaboration To Minimize Opioid Use After Hernia Surgery

University Of Tennessee Medical Center At Knoxville, Pacira Pharmaceuticals, And CQ-Insights Announce Collaboration To Minimize Opioid Use After Hernia Surgery

Continuous quality improvement project aims to optimize patient outcomes after hernia repair

Pacira Pharmaceuticals Stock Trading Halted; FDA Advisory Committee To Review SNDA For EXPAREL® As A Nerve Block For Regional Analgesia

Pacira Pharmaceuticals Stock Trading Halted; FDA Advisory Committee To Review SNDA For EXPAREL® As A Nerve Block For Regional Analgesia

Anesthetic and Analgesic Drug Products Advisory Committee Meeting February 14-15

First Week of March 16th Options Trading For Pacira Pharmaceuticals (PCRX)

First Week of March 16th Options Trading For Pacira Pharmaceuticals (PCRX)

Investors in Pacira Pharmaceuticals Inc. saw new options become available this week, for the March 16th expiration.

WellStar Health System And Pacira Pharmaceuticals Announce Partnership To Minimize Opioid Use And Standardize Outcomes Across Surgical Procedures

WellStar Health System And Pacira Pharmaceuticals Announce Partnership To Minimize Opioid Use And Standardize Outcomes Across Surgical Procedures

Agreement will focus on designing and deploying best practice enhanced recovery protocols across therapeutic areas in 11 Georgia-based hospitals

First Week Of PCRX August 2018 Options Trading

First Week Of PCRX August 2018 Options Trading

Investors in Pacira Pharmaceuticals Inc. saw new options begin trading this week, for the August 2018 expiration.

Illinois Surgical Quality Improvement Collaborative And Pacira Pharmaceuticals, Inc. Announce Collaboration To Minimize Opioid Exposure For Postsurgical Patients

Illinois Surgical Quality Improvement Collaborative And Pacira Pharmaceuticals, Inc. Announce Collaboration To Minimize Opioid Exposure For Postsurgical Patients

Collaboration will develop and distribute evidence-based strategies, education and resources to reduce the overprescribing and optimize the use of opioids across 56 Illinois hospitals

Pacira Announces Promotions Of Scott Braunstein, MD, To Chief Operating Officer And Richard Scranton, MD, To Chief Scientific Officer

Pacira Announces Promotions Of Scott Braunstein, MD, To Chief Operating Officer And Richard Scranton, MD, To Chief Scientific Officer

Expanded roles reflect key accomplishments and demonstrated leadership

Interesting PCRX Put And Call Options For January 2018

Interesting PCRX Put And Call Options For January 2018

Investors in Pacira Pharmaceuticals Inc. saw new options become available this week, for the January 2018 expiration.

Pacira Pharmaceuticals And TELA Bio Announce Equity Agreement

Pacira Pharmaceuticals And TELA Bio Announce Equity Agreement

Pacira to invest up to $25 million in TELA Bio to enhance commercial and clinical initiatives for distinct class of novel surgical implants for soft tissue repair

First Week of PCRX May 2018 Options Trading

First Week of PCRX May 2018 Options Trading

Investors in Pacira Pharmaceuticals Inc. saw new options become available this week, for the May 2018 expiration.

Pacira Pharmaceuticals Stock Sees Short Interest Expand By 13.7%

Pacira Pharmaceuticals Stock Sees Short Interest Expand By 13.7%

The most recent short interest data has been released for the 08/31/2017 settlement date, which shows a 637,865 share increase in total short interest for Pacira Pharmaceuticals Inc. , to 5,288,719, an increase of 13.72% since 08/15/2017.

Pacira Pharmaceuticals, Aetna, And The American Association Of Oral And Maxillofacial Surgeons Join Together In A Program To Reduce Opioid Exposure For Patients Undergoing Wisdom Tooth Extraction

Pacira Pharmaceuticals, Aetna, And The American Association Of Oral And Maxillofacial Surgeons Join Together In A Program To Reduce Opioid Exposure For Patients Undergoing Wisdom Tooth Extraction

The national program aims to reduce the volume of opioids prescribed following wisdom tooth extraction by 50 percent

TheStreet Quant Rating: D (Sell)